# Cellenkos®

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellenkos

- Industry: Biotechnology
- Headquarters: Houston, US
- Website: www.cellenkosinc.com
- Total disclosed funding: $15M
- Latest round: Series A (Nov 4, 2021)
- Investors on record: 1

## About

Cellenkos® Inc. is a biotechnology company focused on developing innovative immune regulatory T-cell therapies, particularly targeting autoimmune diseases and inflammatory disorders with its lead product CK0801.Cellenkos® Inc. is engaged in the development of allogeneic, tissue-targeted immune regulatory T-cell therapies. Founded by Simrit Parmar, the company is headquartered in Houston, US. In November 2021, Cellenkos raised USD 15.00 mn in Series A funding led by BVCF Capital, representing its first significant financing round.Cellenkos, Inc. specializes in developing allogeneic, tissue-targeted, immune regulatory T-cell therapies, focusing on their flagship product, CK0801. This therapy aims to replace defective regulatory T cells in patients with autoimmune diseases, functioning by suppressing T cell activity to restore immune balance. Target conditions include lupus, multiple sclerosis, rheumatoid arthritis, Crohn's disease, and aplastic anemia, primarily serving healthcare providers and specialized treatment centers in the US and select European markets.Cellenkos generates revenue through partnerships with healthcare institutions and biopharmaceutical companies that utilize its therapies, particularly CK0801. The revenue model is based on clinical collaborations and licensing agreements, which may involve upfront payments, milestone payments tied to clinical development, and royalties on future sales, as the company moves through trials and regulatory processes.In November 2021, Cellenkos raised USD 15.00 mn in Series A funding to advance its Treg cell therapy platform, addressing critical unmet needs in autoimmune and inflammatory disorders. The funding will support the development of CK0801 and potential new therapies, as well as the company's plans for geographic expansion into new markets, specifically targeting regions in Europe by 2023.

## Funding rounds

- Series A, Nov 4, 2021, $15M — BVCF Capital

## Investors

- BVCF Capital — Series A